Abstract: Advances in short arc technology and optical filter coatings led to the design and construction of a table-top light source in 1989; the first viable and cost-effective alternative to a laser. The device can deliver over 3 W within a 30 nm band centered at any wavelength from 200 nm to 1200 nm at fluence rates of over 1 W cm$+$MIN@2$/. Its relative biological effectiveness (RBE) in vitro has been proven alongside an argon pumped dye laser and a copper vapor pumped dye laser. These in vitro tests showed an efficiency of hematoporphyrin derivative (HPD) induced cellular photoinactivation close to that of the argon/dye laser (RBE 100%), with a mean RBE for the lamp of 87 $POM 3% (p $LS 0.05). The lamp proved to be superior to that of the copper/dye laser system with an RBE of up to 150% at fluence rates above 50 mWcm$+$MIN@2$/. In vivo tests show that the extent and depth of tumor necrosis are comparable to that of an argon/dye laser. An in situ bioassay using tumor regrowth delay is currently underway. Early clinical trials show clearance of Bowen's disease and actinic keratosis using the same light fluences as costly PDT lasers. !3
展开▼
机译：【摘要】短弧技术和滤光片涂层的发展促使1989年设计并建造了台式光源。激光的第一个可行且具有成本效益的替代品。该设备可以在30 nm波段内以200 nm至1200 nm的任何波长为中心提供3 W以上的功率，通量率超过1 W cm $ + $ MIN @ 2 $ /。它在体外的相对生物学有效性（RBE）已与氩泵浦的染料激光器和铜蒸气泵浦的染料激光器一起被证明。这些体外测试表明，血卟啉衍生物（HPD）诱导的细胞光灭活效率接近于氩/染料激光（RBE 100％），灯的平均RBE为87 $ POM 3％（p $ LS 0.05） 。事实证明，该灯优于铜/染料激光系统，其通量比在50 mWcm $ + $ MIN @ 2 $ /以上时，RBE高达150％。体内试验表明，肿瘤坏死的程度和深度与氩/染料激光相当。目前正在进行利用肿瘤再生长延迟的原位生物测定。早期的临床试验表明，使用与昂贵的PDT激光器相同的光通量，可以清除Bowen病和光化性角化病。 ！3
展开▼
